美国食品和药物管理局在加快生物电子植入物创新的作用,以恢复视力
Michelle Gabriele Sandrian1, Elvin Ng1, Tieuvi Nguyen1
1Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, United States of America.
Journal of neural engineering
|June 6, 2023
概括
本文审查了恢复视力的生物电子植入物监管途径,突出了当前监管科学中的差距. 美国食品和药物管理局 (FDA) 正在积极吸引利益相关者推进这些视力恢复技术.
科学领域:
- 医疗器械 医疗器械
- 神经技术的神经技术
- 眼科医生 眼科 眼科
背景情况:
- 用于视力恢复的生物电子植入物是受食品和药物管理局 (FDA) 监管的医疗器械.
- 本文考察了与这些先进的视力恢复技术相关的监管环境和FDA计划.
更多相关视频
09:29A Standardized Obstacle Course for Assessment of Visual Function in Ultra Low Vision and Artificial Vision
Published on: February 11, 2014
13.1K
10:00Techniques for Processing Eyes Implanted with a Retinal Prosthesis for Localized Histopathological Analysis: Part 2 Epiretinal Implants with Retinal Tacks
Published on: February 14, 2015
11.7K
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
